Veterinary Medicines

CANIGEN DHPPI LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION FOR DOGS

Authorised
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parainfluenza virus, strain Manhattan, Live
  • Canine parvovirus, strain Cornell 780916, Live
  • Canine distemper virus, strain Lederle, Live
Download as PDF

Product identification

Medicine name:
CANIGEN DHPPI LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION FOR DOGS
Canigen CHPPi lyofilisat og væske til injeksjonsvæske, suspensjon til hund
Active substance:
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parainfluenza virus, strain Manhattan, Live
  • Canine parvovirus, strain Cornell 780916, Live
  • Canine distemper virus, strain Lederle, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine adenovirus 2, strain Manhattan, Live
    10000.00
    50% tissue culture infectious dose
    /
    1.00
    unit(s)
  • Canine parainfluenza virus, strain Manhattan, Live
    100000.00
    50% tissue culture infectious dose
    /
    1.00
    unit(s)
  • Canine parvovirus, strain Cornell 780916, Live
    100000.00
    50% tissue culture infectious dose
    /
    1.00
    unit(s)
  • Canine distemper virus, strain Lederle, Live
    1000.00
    50% tissue culture infectious dose
    /
    1.00
    unit(s)
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AD04
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Norway
Available in:
  • Norway
Package description:
  • Cardboard box of 1 vial lyophilisate and 1 vial solvent
  • Plastic box of 100 vials lyophilisate and 100 vials solvent
  • Plastic box of 50 vials lyophilisate and 50 vials solvent
  • Plastic box of 25 vials lyophilisate and 25 vials solvent
  • Plastic box of 10 vials lyophilisate and 10 vials solvent
  • Plastic box of 5 vials lyophilisate and 5 vials solvent
  • Plastic box of 1 vial lyophilisate and 1 vial solvent
  • Cardboard box of 100 vials lyophilisate and 100 vials solvent
  • Cardboard box of 50 vials lyophilisate and 50 vials solvent
  • Cardboard box of 25 vials lyophilisate and 25 vials solvent
  • Cardboard boxof 10 vials lyophilisate and 10 vials solvent
  • Cardboard box of 5 vials lyophilisate and 5 vials solvent

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Virbac
Marketing authorisation date:
Manufacturing sites for batch release:
  • Virbac
Responsible authority:
  • Norwegian Medical Products Agency
Authorisation number:
  • 15-10770
Date of authorisation status change:
Reference member state:
  • France
Procedure number:
  • FR/V/0297/001
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Norwegian (PDF)
Published on: 14/12/2023
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Norwegian (PDF)
Published on: 14/12/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."